Temporal Trends in Hepatitis C–Related Hospitalizations, United States, 2000–2019

Details

• Alternative Title:
  Clin Infect Dis
• Personal Author:
  Hofmeister, Megan G. ; Zhong, Yuna ; Moorman, Anne C. ; Samuel, Christina R. ; Teshale, Eyasu H. ; Spradling, Philip R.
• Description:
  Background.
  
  Hospitalization burden related to hepatitis C virus (HCV) infection is substantial. We sought to describe temporal trends in hospitalization rates before and after release of direct-acting antiviral (DAA) agents.
  
  Methods.
  
  We analyzed 2000–2019 data from adults aged ≥18 years in the National Inpatient Sample. Hospitalizations were HCV-related if (1) hepatitis C was the primary diagnosis, or (2) hepatitis C was any secondary diagnosis with a liver-related primary diagnosis. We analyzed characteristics of HCV-related hospitalizations nationally and examined trends in age-adjusted hospitalization rates.
  
  Results.
  
  During 2000–2019, there were an estimated 1 286 397 HCV-related hospitalizations in the United States. The annual age-adjusted hospitalization rate was lowest in 2019 (18.7/100 000 population) and highest in 2012 (29.6/100 000 population). Most hospitalizations occurred among persons aged 45–64 years (71.8%), males (67.1%), White non-Hispanic persons (60.5%), and Medicaid/Medicare recipients (64.0%). The national age-adjusted hospitalization rate increased during 2000–2003 (annual percentage change [APC], 9.4%; P < .001) and 2003–2013 (APC, 1.8%; P < .001) before decreasing during 2013–2019 (APC, −7.6%; P < .001). Comparing 2000 to 2019, the largest increases in hospitalization rates occurred among persons aged 55–64 years (132.9%), Medicaid recipients (41.6%), and Black non-Hispanic persons (22.3%).
  
  Conclusions.
  
  Although multiple factors likely contributed, overall HCV-related hospitalization rates declined steadily after 2013, coinciding with the release of DAAs. However, the declines were not observed equally among age, race/ethnicity, or insurance categories. Expanded access to DAA treatment is needed, particularly among Medicaid and Medicare recipients, to reduce disparities and morbidity and eliminate hepatitis C as a public health threat.
  
  
• Subjects:
  Adolescent Adult Aged Antiviral Agents Hepacivirus Hepatitis C Hepatitis C, Chronic Hospitalization Humans Male Medicare United States

  More +
• Keywords:
  Direct-acting Antiviral Healthcare Utilization Hepatitis C Hospitalization National Inpatient Sample
• Source:
  Clin Infect Dis. 77(12):1668-1675
• Pubmed ID:
  37463305
• Pubmed Central ID:
  PMC11017377
• Document Type:
  Journal Article
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Volume:
  77
• Issue:
  12
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:b4686571bfadba7a900336b087ce35e0c4ef58fd713d1dab563bea289fff4c84e873522ae040adbede17a5910cebbcc89a57eedde27c4c165f26f1ab467a2e14
• Download URL:
  https://stacks.cdc.gov/view/cdc/154387/cdc_154387_DS1.pdf
• File Type:
  [PDF - 723.44 KB ]